CME/CE Information
We are excited to announce the Targeted Learning for Targeted Treatment: GO2 for Lung Cancer Continuing Medical and Nursing Education for HER2 (ERBB2)-mutant NSCLC activities are now available in the GO2 Global Knowledge Center.
This activity is jointly provided by Global Education Group (Global) and GO2 for Lung Cancer.
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Target Audience
The primary audience for this project is multidisciplinary healthcare professionals (HCPs) involved in the diagnosis, treatment, and longitudinal care of patients with advanced mNSCLC, including those with HER2 (ERBB2)-mutations. This includes medical oncologists, nurse practitioners, physician assistants, oncology pharmacists, molecular pathologists, oncology nurses and navigators, and other team members integral to diagnosis, biomarker testing, treatment selection, and toxicity management, especially those practicing in community, under-resourced, and rural settings, where disparities in access to biomarker testing and targeted therapies remain most pronounced.
Statement of Need/Program Overview
Lung cancer remains the leading cause of cancer-related deaths in the U.S. for both men and women. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer diagnoses, and an estimated 55% to 80% of these patients have a targetable genomic mutation. Identifying these alterations through next-generation sequencing (NGS) testing is critical to delivering timely, effective, and personalized care. This project includes a free and accessible high-quality micro-education 7 course series with companion podcasts, featured topic-webinars, implementation tools, and a resource center that engages and supports a broad array of Healthcare Providers along with a patient testimonial video.
NSCLC Histology and Oncogenesis of HER2 (ERBB2) Mutation in NSCLC
Faculty: Courtney Granville PhD, MSPH| Available to learners from October 16, 2026 – October 16, 2027
Biomarker Testing in Non-Small Cell Lung Cancer Diagnosis
Faculty: Parthi Desai, MD | Available to learners from October 16, 2026 – October 16, 2027
Precision Oncology in HER2 (ERBB2) Mutation and Guideline-Directed Targeted Therapies
Faculty: Julia Rotow, MD| Available to learners from October 23, 2026 – October 23, 2027
Managing Toxicities of Targeted Therapies
Faculty: Kathryn Mileham, MD and Christopher Pallas, MD| Available to learners from October 16, 2026 – October 16, 2027
Closing Gaps in Personalized NSCLC Care Through Implementation of High-Quality Precision Programs
Faculty: Sarah Goldberg, MD, MPH and Paul Stockhammer, MD, PhD| Available to learners from October 23, 2026 – October 23, 2027
Molecular Tumor Boards (MTBs) and Precision Oncology Programs
Faculty: Ryan Nguyen, DO| Available to learners from October 16, 2026 – October 16, 2027
Financial Toxicity and Policy Implications for Access to Biomarker Testing and Targeted Therapies
Faculty: Monica Bryant| Available to learners from October 16, 2026 – October 16, 2027
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Global Education Group and GO2 for Lung Cancer. Global Education Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Global Contact Information
For information about the Joint Accreditation (ACCME, ANCC) of this activity, please contact Global at 303-395-1782 or [email protected].
Course Series
Please click on each course for important information about the CME/CE accreditation for the course.
-
.jpg)
Understanding NSCLC Histology and Oncogenesis of HER2 (ERBB2) Mutation in NSCLC
CourseThis course reviews NSCLC histologic subtypes and HER2 alterations, including mutation, amplification, and overexpression, and explains how HER2-driven signaling pathways (MAPK, PI3K/AKT, PKC, STAT) promote tumor growth and progression.
-
.png)
Biomarker Testing in Non-Small Cell Lung Cancer Diagnosis
CourseExplore the role of comprehensive NGS testing across the NSCLC care continuum, compare biomarker testing strategies, and examine how early identification of HER2 (ERBB2) mutations can inform precision treatment decisions.
-
Precision Oncology in HER2 (ERBB2) Mutation and Guideline-Directed Targeted Therapies
CourseExplore the biology, diagnosis, and management of HER2 (ERBB2)-mutant NSCLC, including molecular characteristics, prognostic implications, targeted therapies, clinical trial evidence, guideline-directed care, and treatment-related toxicities.
-
.png)
Managing Toxicities of Targeted Therapies
CourseLearn to recognize and manage toxicities associated with platinum-based, immunotherapy, and HER2-targeted therapies in NSCLC. Explore proactive strategies to prevent, monitor, and mitigate adverse events to optimize patient outcomes.
-
.png)
Closing Gaps in Personalized NSCLC Care Through Implementation of High-Quality Precision Programs
CourseExplore patient-centered strategies to optimize comprehensive NGS testing, streamline biomarker-driven care, leverage collaborative care models and telehealth, and use quality metrics to improve outcomes for patients with HER2 (ERBB2)-mutant NSCLC.
-
Molecular Tumor Boards (MTBs) and Precision Oncology Programs
CourseExplore the role of molecular tumor boards in NSCLC care, including their impact on biomarker testing, treatment initiation for HER2-mutant disease, and integration into clinical workflows to support personalized treatment decisions.
